Last update Aug. 31, 2020
Very Low Risk
We do not have alternatives for A02AA01; A06AD01 since it is relatively safe.
Suggestions made at e-lactancia are done by APILAM team of health professionals, and are based on updated scientific publications. It is not intended to replace the relationship you have with your doctor but to compound it. The pharmaceutical industry contraindicates breastfeeding, mistakenly and without scientific reasons, in most of the drug data sheets.
Your contribution is essential for this service to continue to exist. We need the generosity of people like you who believe in the benefits of breastfeeding.
Thank you for helping to protect and promote breastfeeding.
A02AA01; A06AD01 is Magnesium Carbonate in ATC Code/s.Is written in other languages:
A02AA01; A06AD01 belongs to these groups or families:
Main tradenames from several countries containing A02AA01; A06AD01 in its composition:
|Oral Bioavail.||15 -20||%|
|VD||0.2 - 0.4||l/Kg|
Write us at email@example.com
e-lactancia is a resource recommended by Asociación Pro Lactancia Materna (APROLAM) of Mexico
Would you like to recommend the use of e-lactancia? Write to us at corporate mail of APILAM
Various magnesium salts, such as carbonate, hydroxide, oxide, peroxide, silicate and trisilicate are used as antacids and carbonate, citrate, oxide, peroxide and sulphate as osmotic laxatives.
Daily magnesium requirements for breastfeeding mothers are estimated at 310 to 360 mg (MedlinePlus 2017); some countries have established figures of up to 450 mg daily (Hall 2010).
Since the last update we have not found any published data on its excretion in breast milk.
Magnesium is a natural component of milk. The average natural concentration of magnesium in milk is 31 mg/L (15 to 64 mg/L) (Dórea 2000, Feeley 1983).
When ingested, magnesium does not concentrate in breastmilk. Its concentration in milk is very stable and depends little on diet (USD 2000) and other factors, including intravenous administration of magnesium sulphate to the mother: the levels of magnesium in milk of mothers treated with intravenous magnesium sulphate increased in clinically non-significant amounts in relation to mothers not in treatment (Cruikshank 1982, Dorea 2000).
Its low oral bioavailability (AEMPS 2017, Morris 1987) hinders transfer to plasma and, therefore, to breastmilk, as well as transfer to infant plasma via breastmilk.
If the intravenous administration of magnesium sulphate is considered compatible with breastfeeding, all the more reason that salts administered orally will also be compatible (Hagemann 1998).
Various medical associations and expert consensus consider the use of various magnesium salts to be safe during breastfeeding (Hale 2019, Briggs 2015, Dennis 2012, Schaefer 2007, Mahadevan 2006, Richter 2005, Nice 2000, Broussard 1998, Idama 1998).
The manufacturer considers the use of magnesium carbonate to be safe during breastfeeding (AEMPS-BAYER 2017).
See below the information of this related product: